Domestic pharmaceutical firms mull product restructuring

A number of domestic pharmaceutical firms are gearing up to concentrate their efforts on profit-making items via intensive product restructuring program designed to eliminate some items with little marketability, lower insurance price, less frequency of prescription and no production record.

A market analyst said, "Of the total reimbursable items, more than half have no production records an...